Kallikrein 7 Antikörper (AA 30-238)

Produktnummer ABIN7873578

Der Kaninchen Polyklonal anti-Kallikrein 7 Antikörper wird verwendet zum Nachweis von Kallikrein 7 in Proben von Ratte. Er wurde validiert für WB, ELISA und IHC (p).

Kurzübersicht für Kallikrein 7 Antikörper (AA 30-238) (ABIN7873578)

Target: Kallikrein 7 (KLK7)

Reaktivität: Ratte

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser Kallikrein 7 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), ELISA, Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Produktdetails anti-Kallikrein 7 Antikörper

Bindungsspezifität: AA 30-238

Verwendungszweck: Kallikrein 7 Antibody / Klk7

Aufreinigung: Antigen affinity purified

Immunogen: An E.coli-derived rat recombinant protein (K30-N238) was used as the immunogen for the Kallikrein 7 antibody.

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: Optimal dilution of the Kallikrein 7 antibody should be determined by the researcher.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Lyophilized

Buffer: 0.5 mg/mL if reconstituted with 0.2 mL sterile DI water

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: After reconstitution, the Kallikrein 7 antibody can be stored for up to one month at 4oC. For long-term, aliquot and store at -20oC. Avoid repeated freezing and thawing.

Details zu Kallikrein 7

Target: Kallikrein 7 (KLK7)

Andere Bezeichnung: Kallikrein 7

Hintergrund: Kallikrein-related peptidase 7 (KLK7) is a serine protease that in humans is encoded by the KLK7 gene. KLK7 is a chymotrypsin-like serine protease of the member of peptidase S1 family. It is synthesized with a signal peptide of 22 amino acids (aa 1-22) and a propeptide region (aa 23-29) that are subsequently cleaved to generate the mature form. Human KLK7 displays about 40 to 60 % amino acid homology with other members of the family. It cleaves proteins with aromatic side chains in the P1 position. KLK7 is abundantly expressed in the skin and is also present in the brain, mammary gland, cerebellum, spinal cord, and kidney. Lower levels of expression have been reported in in salivary glands, uterus, thymus, thyroid, placenta, trachea, and testis. Its levels are shown to be up-regulated in ovarian carcinoma, especially late-stage serous carcinoma. Less differentiated tumors of more advanced stage show higher level KLK7 expression. KLK7 activity is inhibited by zinc and copper ions

UniProt: P36373

Pathways: Komplementsystem